bispecific antibody 2B1

Known as: MoAb 2B1 Bispecific, 2B1 Bispecific Murine MAb, BsAb 2B1 
A monoclonal antibody with potential antineoplastic activity. Specific for both the immunoglobulin G (IgG) receptor CD16 and c-erbB-2, bispecific… (More)
National Institutes of Health

Related topics

Related topics

7 relations

Broader (1)

Antibodies, Bispecific
Antigens, CD16Bispecific Monoclonal AntibodiesERBB2 protein, humanPositive Regulation of Cytolytic Process
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
INTRODUCTION The pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different diseases… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
1999
1999
Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210
Background: MDX-210 is a bispecific antibody (BsAb) with specificity for both the proto-oncogene product of HER-2/neu (c-erbB-2… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
1998
1998
Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
For the treatment of minimal residual disease in patients with leukemias and malignant lymphomas, we constructed a heterodimeric… (More)
Is this relevant?
1998
1998
Peroxynitrite-mediated nitration of tyrosine and inactivation of the catalytic activity of cytochrome P450 2B1.
The addition of peroxynitrite to purified cytochrome P450 2B1 resulted in a concentration-dependent loss of the NADPH- and… (More)
Is this relevant?
1998
1998
Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
The FcR for IgA (Fc alpha RI, CD89) is primarily expressed on cytotoxic immune effector cells. By chemically cross-linking F(ab… (More)
Is this relevant?
1997
1997
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment
 The bispecific monoclonal antibody (bsmAb) 2B1, targeting the extracellular domain of c-erbB-2, the protein product of the HER-2… (More)
  • table 1m2
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
1995
1995
Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
2B1 is a bispecific murine monoclonal antibody (BsMAb) with specificity for the c-erbB-2 and Fc gamma RIII extracellular domains… (More)
Is this relevant?
1995
1995
Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Bispecific monoclonal antibodies (BsmAb) can be used to specifically target tumor cells for cytotoxicity mediated by defined… (More)
Is this relevant?
1993
1993
Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
Bispecific monoclonal antibodies (BsmAb) with specificity for tumor Ag and effector cell trigger molecules have been shown to… (More)
Is this relevant?
1992
1992
In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
Bispecific murine monoclonal antibody 2B1, possessing dual specificity for the human c-erbB-2 protooncogene product and human Fc… (More)
  • table 1
  • figure I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?